Nature of business and basis of presentation - Atrin Acquisition (Details) - Atrin Pharmaceuticals, Inc		3 Months Ended
May 16, 2022 shares	Jun. 30, 2022 shares
Common stock issuable upon conversion outstanding shares issued in merger	29,496,300
Preferred stock conversion ratio	10
Series A Preferred Stock
Series A preferred stock outstanding shares issued in merger	2,949,630	2,949,630
Preferred stock conversion ratio	10

Number of new stock classified as temporary equity issued on acquisition during the period.

No definition available.

Name:	apre_TemporaryEquityStockIssuedDuringPeriodSharesIssuedOnAssetsAcquisition
Namespace Prefix:	apre_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of common shares issuable upon conversion for each share of preferred stock to be converted.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

+ Details

Name:	us-gaap_PreferredStockConvertibleConversionRatio
Namespace Prefix:	us-gaap_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of common shares issuable upon conversion of preferred stock.

+ References

+ Details

Name:	us-gaap_PreferredStockConvertibleSharesIssuable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_AssetAcquisitionAxis=apre_AtrinPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: